1. Home
  2. FOFO vs CMMB Comparison

FOFO vs CMMB Comparison

Compare FOFO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

FOFO

Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

N/A

Current Price

$2.15

Market Cap

19.2M

Sector

N/A

ML Signal

N/A

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$2.79

Market Cap

19.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FOFO
CMMB
Founded
2017
2004
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.2M
19.9M
IPO Year
2025
2023

Fundamental Metrics

Financial Performance
Metric
FOFO
CMMB
Price
$2.15
$2.79
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
5.2K
98.2K
Earning Date
03-13-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.09
$67.75
Revenue Growth
N/A
N/A
52 Week Low
$1.75
$1.35
52 Week High
$68.00
$3.55

Technical Indicators

Market Signals
Indicator
FOFO
CMMB
Relative Strength Index (RSI) 38.84 72.94
Support Level $1.79 $1.49
Resistance Level $2.70 $2.86
Average True Range (ATR) 0.15 0.22
MACD -0.02 0.04
Stochastic Oscillator 6.38 75.03

Price Performance

Historical Comparison
FOFO
CMMB

About FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: